

JUNE 1, 2016 | MINNEAPOLIS, MN

Few companies cast as large a shadow over the Medtech sector as Medtronic.

Whether it be migration toward a "total solutions" strategy, the acquisition of promising new technology start-ups like Twelve, or dramatically expanding its strategic mass through the Covidien acquisition, Medtronic has moved aggressively to continue to thrive under the health care industry's new playing field.

Hear directly from Geoff Martha, the seasoned executive who led the development of Medtronic's global strategic plans, managed the integration of Covidien and was recently tapped to oversee the strategic direction and operational management of four major divisions central to Medtronic's growth rate.

Stacy Enxing Seng, who recently joined Lightstone Ventures as a Venture Partner, and formerly led Covidien's Vascular Therapies business, will ask Geoff Martha about Medtronic's much-talked about drive into global services, its appetite for future acquisitions and his thoughts on the future possibilities within Medtech.

What Medtech Means to Medtronic

Keynote Speaker



Geoff Martha
Executive Vice President,
Restorative Therapies Group
Medtronic

Interviewed By



Stacy Enxing Seng
Venture Partner & Independent Director
Lightstone Ventures